Intuitive Surgical, Inc. (ISRG)
Is Innovation-Led Growth Driving ISRG's Revenues Above Procedures?
ISRG's Q1 results show revenues outpacing procedures as da Vinci 5 drives pricing power, signaling a shift toward innovation-led, value-based growth.
Intuitive Surgical's Selloff Sets Up a 30% Rebound Opportunity
Intuitive Surgical's NASDAQ: ISRG primary headwinds are its high valuation and slowing growth. The combination has weighed on price action since early 2025 and is unlikely to go away soon.
The Biggest Takeaway From ISRG Earnings
The key takeaway from Intuitive Surgical's (ISRG) Q1 2026 results is the implementation of a fundamental “Platform Refresh Wall.” In addition to the $2.50 EPS exceeding expectations and a revenue growth of 23%, this cycle reshapes the competitive environment for the upcoming decade.
Intuitive Surgical, Inc. $ISRG Holdings Raised by Caprock Group LLC
Caprock Group LLC boosted its stake in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 23.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,355 shares of the medical equipment provider's stock after buying an additional 2,161 shares during the
B. Metzler seel. Sohn & Co. AG Sells 1,776 Shares of Intuitive Surgical, Inc. $ISRG
B. Metzler seel. Sohn and Co. AG lessened its holdings in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 8.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,701 shares of the medical equipment provider's stock after selling 1,776 shares during the quarter. B.
Intuitive Surgical: Forget The 40x P/E. Focus On The 10-Year Potential (Upgrade)
Intuitive Surgical is upgraded to a 'cautious buy' despite a premium valuation, reflecting its monopoly position and robust long-term growth prospects. ISRG delivered a strong Q1 with 23% YoY revenue growth, 17% procedure growth, and notable margin expansion, demonstrating operating leverage and recurring revenue strength. The Da Vinci and Ion systems' installed base continues to ramp up, supporting a compounding financial model with high recurring revenue and long-term customer relationships.
Intuitive Surgical Is A Buy Despite Soaring Post-Earnings
Intuitive Surgical demonstrated robust Q1 adoption metrics, accelerating revenue growth, and expanding margins, reinforcing the long-term growth thesis. ISRG raised its full-year outlook for da Vinci procedure growth and gross margin, signaling improved near-term prospects despite prior soft 2026 guidance. Q1 financials outperformed expectations, with revenue up 23% YoY and adjusted EPS up 38%, driven by strong pricing power and operational efficiency.
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?
The robots aren't coming in the healthcare sector; they are already here, and Intuitive Surgical sells them.
Intuitive Surgical Reports Another Blowout Quarter: Time to Buy the Stock?
The surgical robotics company's latest quarterly report was exceptional across the board.
Intuitive Surgical: Strong Quarter, Mispriced Stock
Intuitive Surgical delivered strong Q1 results, with 23% revenue growth, margin expansion, and EPS beating estimates by $0.39. ISRG raised its procedure growth guidance to 13.5%-15.5% and gross margin to 67.5%-68.5%, despite cost and regional headwinds. Key risks include cost inflation, softness in China and Japan, and healthcare CapEx sensitivity, but ISRG's market leadership and recurring revenue model remain robust.
Intuitive Surgical Q1 results top estimates as robotic surgery demand accelerates
Intuitive Surgical Inc (NASDAQ:ISRG, XETRA:IUI1) reported stronger-than-expected quarterly results, supported by continued adoption of its robotic-assisted surgical platforms and solid procedural growth across key markets, according to UBS analysts. Shares of Intuitive traded up 8% following the release of the report.
ISRG Stock Up as Q1 Earnings & Sales Beat Estimates on Procedure Growth
ISRG jumps after Q1 EPS and revenues beat estimates as da Vinci and Ion procedure growth powers recurring sales and da Vinci 5 placements.
